In summary, we found that aberrant TRPM8 activity in sensory neurons was a crucial and a very early effect of oxaliplatin-treatment, an effect that seems to be linked to oxaliplatin-induced neuropathy and that may be targeted pharmacologically to alleviate oxaliplatin-induced pain. The gene discussed is TRPM8; the disease is neuropathy.